🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Australia / NCT06651580
Recruiting Observational

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study

NCT06651580 · tracked via the Priya Life Science Australia tracker
Phase
Observational
Started
2021-04-01
Last updated
2026-09-11

Condition(s) studied

Chronic PancreatitisExocrine Pancreas CarcinomaRecurrent Acute Pancreatitis

Investigational drug(s) / intervention(s)

Biospecimen CollectionQuality-of-Life AssessmentQuestionnaire Administration

Biospecimen Collection: Undergo collection of blood, saliva, urine or stool samples

Quality-of-Life Assessment: Complete QoL assessment

Questionnaire Administration: Complete questionnaire

Study summary

This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute recurrent pancreatitis and chronic pancreatitis may help identify patients who are at risk of pancreatic cancer.

Eligibility

Sex
ALL
Min age
—
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria: * All subjects/parents must sign an informed consent and/or assent indicating that they are aware of the investigational nature of this study * Subjects/parents must have signed an authorization for the release of their or their child's protected health information * All children must be under 18 years of age at the time of enrollment * All children providing samples should fit the ARP or CP inclusion criteria defined below: * Acute pancreatitis (AP): AP is defined as requiring 2 of the following: * Abdominal pain compatible with AP * Serum amylase and/or lipase values \>= 3 times upper limits of normal * Imaging findings of AP, such as gland enlargement, acute inflammatory changes, and fluid collections * ARP is defined as: At least 2 episodes of acute pancreatitis with complete resolution of pain and a \>= 1 month pain-free interval between episodes * Chronic Pancreatitis: * Children with at least: * One irreversible structural change in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes * Irreversible structural changes: * Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound \[abd US\], magnetic resonance imaging/magnetic resonance cholangiopancreatography \[MRI/MRCP\], computerized tomography \[CT\], endoscopic retrograde cholangiopancreatography \[ERCP\], endoscopic US \[EUS\]) * Ductal obstruction or stricture/dilatation/irregularities that are persistent (for \>= 2 months) on any imaging * Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP * Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages) Exclusion Criteria: * Subjects must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the subject's ability to tolerate study interventions

Primary outcome measure(s)

Trial sites (26)

FacilityCityRegionStatus
Children's Hospital Los Angeles Los Angeles California Recruiting
Cedars Sinai Medical Center Los Angeles California Recruiting
UCSF Benioff Children's Hospital Oakland Oakland California Recruiting
Stanford Cancer Institute Palo Alto Palo Alto California Recruiting
University of Colorado Denver Colorado Recruiting
Emory University Hospital/Winship Cancer Institute Atlanta Georgia Recruiting
Riley Hospital for Children Indianapolis Indiana Recruiting
University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa Recruiting
Ochsner Medical Center Jefferson New Orleans Louisiana Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland Recruiting
Boston Children's Hospital Boston Massachusetts Recruiting
University of Minnesota/Masonic Children's Hospital Minneapolis Minnesota Recruiting
Washington University School of Medicine St Louis Missouri Recruiting
Cincinnati Children's Hospital Medical Center Cincinnati Ohio Recruiting
Nationwide Children's Hospital Columbus Ohio Recruiting
Children's Hospital of Philadelphia Philadelphia Pennsylvania Recruiting
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania Recruiting
University of Texas Southwestern/Children's Medical Center Dallas Texas Recruiting
M D Anderson Cancer Center Houston Texas Recruiting
Texas Children's Hospital Houston Texas Recruiting
Children's Hospital of San Antonio San Antonio Texas Recruiting
Children's Hospital of Wisconsin Milwaukee Wisconsin Recruiting
Sydney Children's Hospital Randwick New South Wales Recruiting
Hospital for Sick Children Toronto Ontario Recruiting
The Montreal Children's Hospital of the MUHC Montreal Quebec Recruiting
Hadassah University Hospital Jerusalem Israel Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06651580 on ClinicalTrials.gov ↗ ← All trials in Australia